Doug Guarino

Jon Russell

Director of Corporate Relations

Vice President of Finance

Net revenue of $755.8 million for the fourth quarter of 2012, compared to $651.1 million for the fourth quarter of 2011. Non-GAAP adjusted net revenue, which includes $0.8 million in estimated revenue related to acquired software license contracts not recognized for GAAP purposes for the fourth quarter of 2012 due to business combination accounting rules, was $756.5 million for the fourth quarter of 2012, compared to $652.6 million for the fourth quarter of 2011.

Net loss of $62.7 million attributable to common stockholders of Alere Inc., and respective net loss per diluted common share of $0.84, for the fourth quarter of 2012, compared to net loss of $363.9 million attributable to common stockholders of Alere Inc., and respective net loss per diluted common share of $4.67, for the fourth quarter of 2011.

Non-GAAP adjusted net income per diluted common share of $0.55 for the fourth quarter of 2012, compared to non-GAAP adjusted net income per diluted common share of $0.70 for the fourth quarter of 2011.

Net product and services revenue from our Professional Diagnostics segment was $584.1 million in the fourth quarter of 2012, compared to net product and services revenue of $495.9 million in the fourth quarter of 2011. Non-GAAP adjusted net product and services revenue from our Professional Diagnostics segment, which includes $0.8 million in estimated revenue related to acquired software license contracts not recognized for GAAP purposes for the fourth quarter of 2012 due to business combination accounting rules, was $584.9 million in the fourth quarter of 2012, compared to non-GAAP adjusted net product and services revenue of $497.4 million in the fourth quarter of 2011. Recent professional diagnostics acquisitions contributed $77.9 million of incremental net revenue compared to the fourth quarter of 2011.

North American influenza sales increased to $23.0 million for the fourth quarter of 2012, from $8.3 million for the fourth quarter of 2011.

Excluding the impact of the change in North American influenza revenues and the impact on revenues from the reduction in our U.S. meter-based Triage product sales, currency adjusted organic growth in our Professional Diagnostics segment was 5%.

Net product and services revenue from our Health Information Solutions (formerly known as Health Management) segment was $131.0 million in the fourth quarter of 2012, compared to $125.9 million in the fourth quarter of 2011 and $135.1 million in the third quarter of 2012. The increase in revenue from the fourth quarter of 2011 was related primarily to increased revenues from our home coagulation monitoring programs.

Included in royalty revenues in the fourth quarter of 2012 was $11.0 million associated with the license of certain of our molecular intellectual property. Partially offsetting this, and included in interest and other income (expense), was a charge of a $3.9 million associated with the settlement of a prior year dispute with a former distributor.

Net product sales and services revenue

License and royalty revenue

Net revenue

Cost of net revenue

Gross profit

Gross margin

Operating expenses:

Research and development

Selling, general and administrative

Goodwill impairment charge

Total operating expenses

Operating income (loss)

Interest and other income (expense), net

Loss before benefit for income taxes

Benefit for income taxes

Loss before equity earnings of unconsolidated entities, net of tax

Equity earnings of unconsolidated entities, net of tax

Net loss

Less: Net income attributable to non-controlling interests

Net loss attributable to Alere Inc. and Subsidiaries

Preferred stock dividends

Net loss available to common stockholders

Net loss per common share—basic and diluted

Weighted average shares—basic and diluted

Net product sales and services revenue

License and royalty revenue

Net revenue

Cost of net revenue

Gross profit

Gross margin

Operating expenses:

Research and development

Selling, general and administrative

Goodwill impairment charge

Total operating expenses

Operating income (loss)

Interest and other income (expense), net

Loss before before benefit for income taxes

Benefit for income taxes

Loss before equity earnings of unconsolidated entities, net of tax

Equity earnings of unconsolidated entities, net of tax

Net loss

Less: Net income attributable to non-controlling interests

Net loss attributable to Alere Inc. and Subsidiaries

Preferred stock dividends

Preferred stock repurchase

Net loss available to common stockholders

Net loss per common share—basic and diluted

Weighted average shares—basic and diluted

ASSETS

CURRENT ASSETS:

Cash and cash equivalents

Restricted cash

Marketable securities

Accounts receivable, net

Inventories, net

Prepaid expenses and other current assets

Total current assets

PROPERTY, PLANT AND EQUIPMENT, NET

GOODWILL AND OTHER INTANGIBLE ASSETS, NET

DEFERRED FINANCING COSTS AND OTHER ASSETS, NET

Total assets

LIABILITIES AND STOCKHOLDERS’ EQUITY

CURRENT LIABILITIES:

Short-term debt and current portion of long-term debt

Other current liabilities

Total current liabilities

LONG-TERM LIABILITIES:

Long-term debt, net of current portion

Deferred tax liability

Other long-term liabilities

Total long-term liabilities

Redeemable non-controlling interest

TOTAL EQUITY

Total liabilities and equity

Reconciliation to Non-GAAP Adjusted Operating Income ⁽¹⁾

Operating income (loss)

Adjustment related to acquired software license contracts (1)

Amortization of acquisition-related intangible assets

Restructuring charges

Stock-based compensation expense

Goodwill impairment charge

Acquisition-related costs

Fair value adjustments to acquisition-related contingent consideration

Non-cash charge associated with acquired inventory

Non-GAAP adjusted operating income

Reconciliation to Non-GAAP Adjusted Net Income ⁽¹⁾

Net loss available to common stockholders

Adjustment related to acquired software license contracts (1)

Amortization of acquisition-related intangible assets

Restructuring charges

Stock-based compensation expense

Goodwill impairment charge

Acquisition-related costs

Fair value adjustments to acquisition-related contingent consideration

Realized foreign currency gain associated with a bank account funded for the acquisition of Axis-Shield plc

Gain related to previously-owned shares of Axis-Shield plc recorded in connection with the completion of the acquisition during the fourth quarter of 2011.

Non-cash charge associated with acquired inventory

Interest expense recorded in connection with fees paid for certain debt modifications and the termination of our senior secured credit facility and related interest rate swap agreement

Expense associated with extinguishment of debt

Income tax effects on items above

Non-GAAP adjusted net income available to common stockholders

Net income (loss) per diluted common share

Non-GAAP adjusted net income per diluted common share

Weighted average shares—diluted

Non-GAAP adjusted weighted average shares—diluted

In calculating “non-GAAP adjusted operating income” and “non-GAAP adjusted net income”, the Company excludes (i) certain non-cash charges, including amortization expense and stock-based compensation expense, (ii) non-recurring charges and income, and (iii) certain other charges and income that have a significant positive or negative impact on results yet do not occur on a consistent or regular basis in its business. In determining whether a particular item meets one of these criteria, management considers facts and circumstances that it believes are relevant. Management believes that excluding such charges and income from operating income and net income or loss allows investors and management to evaluate and compare the Company’s operating results from continuing operations from period to period in a meaningful and consistent manner. Due to the frequency of their occurrence in its business, the Company does not adjust operating income or net income or loss for the costs associated with litigation, including payments made or received through settlements. It should be noted that “non-GAAP adjusted operating income” and “non-GAAP adjusted net income” are not standard financial measurements under accounting principles generally accepted in the United States of America (“GAAP”) and should not be considered as an alternative to operating income and net income or loss or cash flow from operating activities, as a measure of liquidity or as an indicator of operating performance or any measure of performance derived in accordance with GAAP. In addition, all companies do not calculate non-GAAP financial measures in the same manner and, accordingly, “non-GAAP adjusted operating income” and “non-GAAP adjusted net income” presented in this press release may not be comparable to similar measures used by other companies.

Reconciliation to Non-GAAP Adjusted Operating Income ⁽¹⁾

Operating income (loss)

Adjustment related to acquired software license contracts (1)

Amortization of acquisition-related intangible assets

Restructuring charges

Stock-based compensation expense

Goodwill impairment charge

Acquisition-related costs

Fair value adjustments to acquisition-related contingent consideration

Non-cash charge associated with acquired inventory

Fair value write-down in connection with an idle facility

Expenses incurred in connection with the sale of our vitamin and nutritional supplements business

Non-GAAP adjusted operating income

Reconciliation to Non-GAAP Adjusted Net Income ⁽¹⁾

Net loss available to common stockholders

Adjustment related to acquired software license contracts

Amortization of acquisition-related intangible assets

Restructuring charges

Stock-based compensation expense

Goodwill impairment charge

Acquisition-related costs

Fair value adjustments to acquisition-related contingent consideration

Interest expense recorded in connection with fees paid for certain debt modifications and the termination of our senior secured credit facility and related interest rate swap agreement

Expense associated with extinguishment of debt

Non-cash charge associated with acquired inventory

Gain in connection with the formation of a joint venture

Realized foreign currency gain associated with a bank account funded for the acquisition of Axis-Shield plc

Realized foreign currency loss associated with the settlement of an acquisition-related contingent consideration obligation

Fair value write-down in connection with an idle facility

Expenses incurred in connection with the sale of our vitamin and nutritional supplements business

Gain related to previously-owned shares of Axis-Shield plc recorded in connection with the completion of the acquisition during the fourth quarter of 2011.

Non-cash income allocated to net income available to common stockholders as a result of repurchases of preferred shares

Income tax effects on items above

Non-GAAP adjusted net income available to common stockholders

Net income (loss) per diluted common share

Non-GAAP adjusted net income per diluted common share

Weighted average shares—diluted

Non-GAAP adjusted weighted average shares—diluted

In calculating “non-GAAP adjusted operating income” and “non-GAAP adjusted net income”, the Company excludes (i) certain non-cash charges, including amortization expense and stock-based compensation expense, (ii) non-recurring charges and income, and (iii) certain other charges and income that have a significant positive or negative impact on results yet do not occur on a consistent or regular basis in its business. In determining whether a particular item meets one of these criteria, management considers facts and circumstances that it believes are relevant. Management believes that excluding such charges and income from operating income and net income or loss allows investors and management to evaluate and compare the Company’s operating results from continuing operations from period to period in a meaningful and consistent manner. Due to the frequency of their occurrence in its business, the Company does not adjust operating income or net income or loss for the costs associated with litigation, including payments made or received through settlements. It should be noted that “non-GAAP adjusted operating income” and “non-GAAP adjusted net income” are not standard financial measurements under accounting principles generally accepted in the United States of America (“GAAP”) and should not be considered as an alternative to operating income and net income or loss or cash flow from operating activities, as a measure of liquidity or as an indicator of operating performance or any measure of performance derived in accordance with GAAP. In addition, all companies do not calculate non-GAAP financial measures in the same manner and, accordingly, “non-GAAP adjusted operating income” and “non-GAAP adjusted net income” presented in this press release may not be comparable to similar measures used by other companies.

Professional Diagnostics Segment

Cardiology

Infectious disease

Toxicology

Diabetes

Other ⁽¹⁾

Professional diagnostics net product sales and services revenue ⁽¹⁾

License and royalty revenue

Professional diagnostics net revenue

Health Information Solutions Segment

Disease and case management

Wellness

Women’s & children’s health

Patient self-testing services

Health information solutions net revenue

Revenues are presented in accordance with Generally Accepted Accounting Principles and exclude an adjustment of $0.8 and $1.5 in revenue related to acquired software license contracts which were not recognized during the three months ended December 31, 2012 and 2011, respectively, and $4.1 and $1.5 during the year ended December 31, 2012 and 2011, respectively, due to business combination accounting rules.